Sabizabulin (VERU-111), an novel microtubule inhibitor, significantly reduced mortality in hospitalized patients with moderate to severe Covid-19 at high risk for acute respiratory distress syndrome and death according to an interim analysis from a randomized, global phase 3 clinical trial published this week in The New England Journal of Medicine Evidence.
Latest developments at PurSolutions
Follow us on social media for the most up-to-date news about PurSolutions and exciting cytoskeleton protein content.
After reviewing many exceptional applications, our panel has selected the recipient of the PurSolutions’ 2021 Reagent Scholarship: Mr. Narendran Annadurai Graduate Student Palacky University Olomouc Czech Republic Mr. Annadurai is pursuing the development of tau aggregation inhibitors for neurodegenerative diseases including Alzheimer’s disease. He will primarily be using in vitro aggregation assays and microscopy techniques.
As discussed in our previous article back in March 2020, it has been shown that coronavirus spike proteins interact with cytoskeleton filaments (i.e. microtubules and actin) for internalization into host cells – a critical step in viral pathogenesis. It has also been shown for some coronaviruses that targeting the cytoskeleton with tubulin or actin inhibitors
Dear Researchers, In light of the rapidly changing global health situation resulting from the COVID-19 virus, PurSolutions is committed to supporting researchers in their efforts to discover more about the virus and bring us closer to an effective vaccine or treatment. As you may know, the structure of the COVID-19 spike protein was discovered a
Ashley Arthur, a 5th year graduate student at the University of Minnesota, has been selected as the recipient of PurSolutions’ 2019 Reagent Scholarship. As a lab member in Dr. Titus’ lab, Ashley has been allowed to pursue her passion and curiosity of molecular motors and the cytoskeleton. Ashley states that Dr. Titus and the University
PurSolutions, LLC is one of the 12 recipients selected to receive LaunchTN Funding. Nashville, Tenn. – On January 8, 2019, Launch Tennessee (LaunchTN) announced the 12 selected recipients of the Tennessee Small Business Innovation Research / Small Business Technology Transfer (SBIR/STTR) Matching Fund Grant program. LaunchTN is developed and funded by the Tennessee Department of Economic
PurSolutions partnered with Antibodies-Online to distribute products to over 50 countries on 3 continents. Antibodies-Online is known as the premier online marketplace for proteomic products.
PurSolutions co-founders Dr. Emma Sturgill and Mr. Beattie Sturgill present their “lessons learned” to the National Science Foundation
Emma and Beattie attended and presented at the NSF SBIR/STTR Phase I Grantee Workshop held on March 19th-21st, 2018 in Arlington, VA. The workshop included featured speakers, entrepreneurial networking, presentations, and the Phase I “Beat-the-Odds Boot Camp”. The NSF Boot Camp provides an immersive experience that pushes companies to develop stronger business models, market strategies,
PurSolutions co-founder Dr. Emma Sturgill represents life science startups at the Tennessee General Assembly
Emma was invited to speak on behalf of life science startups in Tennessee to the Tennessee General Assembly Business and Utilities committee. She shared our story, successes, and hurdles encountered as a small business in the life science industry.